Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.83 USD | +1.39% | +9.75% | -2.43% |
05-17 | HC Wainwright Adjusts Kala Pharmaceuticals Price Target to $18 From $21, Maintains Buy Rating | MT |
05-14 | KALA BIO, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.43% | 19.24M | |
+42.69% | 749B | |
+38.93% | 605B | |
-6.87% | 351B | |
+18.74% | 328B | |
+6.76% | 292B | |
+18.91% | 248B | |
-2.41% | 214B | |
+11.13% | 216B | |
+2.64% | 167B |
- Stock Market
- Equities
- KALA Stock
- News KALA BIO, Inc.
- Transcript : Kala Pharmaceuticals, Inc. Presents at BofA Securities 2020 Health Care Conference, May-13-2020 04